News FDA starts review of Regeneron's drug for rare disease FOP Can Regeneron's drug for ultra-rare bone disease FOP pick up the baton from Ipsen's Sohonos, whose growth has stalled?
News Regeneron drug on track to be second FOP treatment There is only one approved drug for ultra-rare disease FOP on the market, but Regeneron is hoping to add a second.
News FDA sets new decision date for Ipsen’s FOP therapy US agency sets 23rd August deadline for palovarotene review as Ipsen files more clinical data.
News Ipsen adds Blueprint's FOP rare disease drug to pipeline for... Ipsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a licence to develop and market a drug for the rare disease fibrodysplasia ossifican
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
